Biotechnology continues to evolve, and 2015 stands as the most important year of the industry’s existence to date. With several companies blossoming into major medical players both in the United States and around the world, it would suffice to say 2015 truly was an insane year. With an even bigger and brighter future to come, here is a look back at some of the most impressive companies and technologies to emerge out of the previous year.
Anacor Pharmaceuticals (ANAC)
A company doesn’t see a 248% increase in its stock value over a single year without drastic improvements and new medical treatments released. Anacor Pharmaceuticals (ANAC) produces a toenail-fungus-fighting drug tallied a $19.1 million net profit on its own after receiving FDA approval in July of 2014. Instead of using the traditional method of chemically treated medication, this biotech medication has helped bolster the company and anyone who suffers from the often embarrassing issue. Beyond the treatment of toenail fungus, the company recently released trial results for a a therapy used to treat eczema. Early FDA approval filings are set for the first quarter of 2016, and should it prove successful, it likely would become one of the top selling biotech medicines in the United States with 31 million Americans affected by the condition.
The fight against cancer and associated conditions remains one of the most important and often illusive forms of treatment in the medical community. Exelixis fell under scrutiny several years earlier with a failed prostate cancer drug. However, through the failure can a new medical and new success, allowing the company’s stock (EXEL) to jump 292% over the course of 2015. The company received FDA approval for a its Cotellic drug. Designed to treat melanoma when used along side Zelboraf, a medication produced by Roche Holdings, it stands as a major improvement in the treatment of this serious form of skin cancer. Additionally, the company just completed a late stage trial of a biotech medication known as Cometiq, which is used to fight kidney cancer. Patients who used the drug saw a reduced risk of death by 42%. In December, the company filed for FDA approval on the kidney drug and now waits for official approval sometime in the first quarter of 2016.
Eagle Pahrmaceuticals (EGRX)
Eagle Pharmaceuticals stands as the top performing biotech company over the course of 2015. With an increase stock value (EGRX) of 476% over the year, no other company listed on the NASDAQ Biotechnology Index ETF has made this kind of a jump. A major advancement made by the company sits in its ready to use bivalirudin, which is currently in the approval stage by the FDA. The advancement in this biotech medical treatment stands as a major strive not only for the industry, but for the medical communicate as a whole. The drug is a rapid infusion drug designed to target chronic lymphocytic leukemia and B-cell non-Hodgkins lymphoma. Cancer research has progressed rapidly in recently years, with the advancement of treatments coming in many forms. While the drug has tested extremely positively in tests, should the medication and treatment receive FDA approval, it will prove a major advancement.
Not all advancements have come within the business sector. Improvements have come from in-house college testing and research. The Cancer spit test, designed by researchers at UCLA, have found a way to detect oral cancer from saliva. Instead of requiring the direct removal of tissue from the mouth, this test allows the detection of cancer by identifying proteins through a sensor emitting fluorescent light. This test may be used in other disease diagnostics.